Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Osiris Therapeutics, Inc. (OSIR) Stock Discontinues Trial Enrollment

Osiris Therapeutics, Inc. (NASDAQ:OSIR) took it on the chin yesterday morning after the company released news through an 8-K filing. Today, we’ll talk about that news, what we’re currently seeing from the stock, and what we can expect to see from OSIR ahead.

emergency, room, doctor, sick, group, latin, medical, profession, patient, doc, concept, life, middle, clinic, male, corridor, occupation, service, gurney, ill, worker, female,

Syda Productions/

OSIR Announces Enrollment Termination Through 8-K Filing

While most big news is announced via press release, it seems as though Osiris Therapeutics, Inc. (NASDAQ:OSIR) is hoping that this doesn’t go too far. In an 8-K filing, the company informed investors that it would be terminating enrollment on its OTI-15-01 Phase III clinical trial. As far as a reason for termination goes, the company said that it is looking to allocate more of its development resources into other clinical trials. Here’s what the form 8-K filing had to offer with regard to the decision made by OSIR:

On October 14, 2016, the Company commenced steps to terminate enrollment in its OTI-15-01 Phase III Clinical Trial. The trial was investigating the safety and efficacy of OTI-15091, a cryopreserved human amniotic membrane, in patients suffering from chronic DFUs that have not responded to standard of care therapy. Patients currently enrolled in the trial will continue with their current course of treatment and scheduled visit assessments, as outlined in the protocol. The decision to terminate further enrollment in the OTI-15-01 trial reflects the Company’s desire to allocate more of its research and development resources to other clinical programs, including its new cellular drug platform technology. The Company presently anticipates the new platform will have utility across multiple indications in wound care, orthopedics and sports medicine.”

What We’re Seeing From The Stock

While we would expect to see a big downturn in OSIR following news like this, it seems as though most investors are giving the company a pass. After the early declines yesterday, the stock rebounded to close the day at level ground, and has actually pushed up by 0.92% in trading this morning.

What We Can Expect To See Moving Forward

Moving forward, I have a relatively bearish opinion of what we can expect to see from Osiris Therapeutics, Inc. (NASDAQ:OSIR). First and foremost, there’s got to be more to this. There has to be a reason that this big announcement was seemingly designed to fly under the radar, and that concerns me. At the end of the day, the discontinuation of enrollment means one of two things – either the company has enough samples currently enrolled in the trial to show meaningful results, or the trial isn’t going well. Given the way this was handled, I would say that OSIR is likely dealing with the latter. All in all, I’m expecting to see declines ahead.

Follow Osiris Therapeutics Inc. (NASDAQ:OSIR)
Trade (NASDAQ:OSIR) Now!

Note: This article was written by Joshua Rodriguez, owner and founder of CNA Finance. If you would like to connect with Joshua, you can do so by emailing him at!

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!